Year Published
- 2008 (3) Apply 2008 filter
- (-) Remove 2009 filter 2009
- 2010 (7) Apply 2010 filter
- 2011 (4) Apply 2011 filter
- 2012 (2) Apply 2012 filter
- 2013 (0)
- 2014 (0)
- 2015 (1) Apply 2015 filter
- 2016 (9) Apply 2016 filter
- (-) Remove 2017 filter 2017
- (-) Remove 2018 filter 2018
- 2019 (2) Apply 2019 filter
- 2020 (0)
- 2021 (0)
Research Topics
Populations
Types of Research
Geography
- East Africa Region and Selected Countries (1) Apply East Africa Region and Selected Countries filter
- Global (5) Apply Global filter
- South Asia Region and Selected Countries (2) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (11) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (1) Apply West Africa Region and Selected Countries filter
Dataset
Current search
- (-) Remove Food Security & Nutrition filter Food Security & Nutrition
- (-) Remove 2009 filter 2009
- (-) Remove 2017 filter 2017
- (-) Remove 2018 filter 2018
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove Labor & Time Use filter Labor & Time Use
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
Cash transfer programs are interventions that directly provide cash to target specific populations with the aim of reducing poverty and supporting a variety of development outcomes. Low- and middle-income countries have increasingly adopted cash transfer programs as central elements of their poverty reduction and social protection strategies. Bastagli et al. (2016) report that around 130 low- and middle-income countries have at least one UCT program, and 63 countries have at least one CCT program (up from 27 countries in 2008). Through a comprehensive review of literature, this report primarily considers the evidence of the long-term impacts of cash transfer programs in low- and lower middle-income countries. A review of 54 reviews that aggregate and summarize findings from multiple studies of cash transfer programs reveals largely positive evidence on long-term outcomes related to general health, reproductive health, nutrition, labor markets, poverty, and gender and intra-household dynamics, though findings vary by context and in many cases overall conclusions on the long-term impacts of cash transfers are mixed. In addition, evidence on long-term impacts for many outcome measures is limited, and few studies explicitly aim to measure long-term impacts distinctly from immediate or short-term impacts of cash transfers.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.
On July 10, 2009 at the Italy G8 summit, attendees issued a joint statement pledging to contribute $20 billion towards agricultural development and food security in the developing world over the next three years. This research brief notes the status of the contributions made to the L’Aquila Food Security Initiative and whether any of the $20 billion will be allocated to agricultural research. We conclude that no declarations have been made as of September 2009 on how much of the $20 billion will be allocated to agricultural research, and which types of research will be funded by the initiative.
Yam is a major staple in West and Central Africa and an important supplementary food in East Africa. In Sub-Saharan Africa (SSA), virtually all yams are produced for human consumption, with women responsible for processing yams for consumption. This brief provides an overview of the role of women in yam production, and provides a framework for analyzing barriers to women and technology’s impact on women throughout the cropping cycle. We find that though yam was traditionally considered a man’s crop, it is clear that women farmers contribute greatly to yam cultivation, especially during weeding, harvesting, and processing. Propagation of improved varieties with resistance to pests and diseases like yam mosaic disease has great potential to benefit women farmers. Increased yields and lower post-harvest losses will increase household food security. However, because yams extract high amounts of nutrients from the soil, soil and land management techniques are necessary to ensure future gains in yield. Women’s groups serve as potential venues for dissemination of new yam cultivation and processing technologies. Additionally, women’s groups can undertake new propagation techniques as income generating activities. Women farmers need increased extension efforts to fully benefit from technology improvements.
Though not indigenous to Sub-Saharan Africa (SSA), cassava plays, to varying degrees, five major roles in African development: famine-reserve crop, rural food staple, cash crop for urban consumption, livestock feed, and industrial raw material. Cassava production in SSA was historically a significant staple crop for smallholder farmers and continues to be the second most important food crop in Africa (after maize) in terms of calories consumed. Subsistence crops such as cassava are often considered women’s crops with the standard explanation that women are responsible for feeding the family and thus prefer to grow crops for the household. This brief reviews the role that women play in cassava production, and considers ways to better address gender issues from planting through post-harvest production. We find that the potential gains to cassava production made possible through improved technology will not be fully realized without the participation of women farmers and without women farmers having access to credit, markets, and extension services. Additionally, evidence from SSA suggests that labor for harvesting and processing, rather than labor for weeding, has become the key labor constraint for cassava, and addressing this concern may be more important than further yield increases for raising production levels.